March 3 (Reuters) - Apogee Therapeutics APGE.O:
APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1 RESULTS FROM THE APG990 HEALTHY VOLUNTEER TRIAL, UNLOCKING POTENTIAL MAINTENANCE DOSING EVERY THREE AND SIX MONTHS FOR APG279 (APG777 + APG990)
APOGEE THERAPEUTICS INC - APG990 WELL TOLERATED UP TO 1,200MG DOSES
APOGEE THERAPEUTICS INC - MOST COMMON ADVERSE EVENT FOR APG990 WAS HEADACHE
APOGEE THERAPEUTICS INC - NO SEVERE ADVERSE EVENTS OR STUDY DISCONTINUATIONS FOR APG990
APOGEE THERAPEUTICS INC - TO INITIATE PHASE 1B TRIAL OF APG279 AGAINST DUPIXENT IN 2025
Source text: ID:nGNX4V8GW9
Further company coverage: APGE.O